cas 2081-44-9|| where to buy oxan-4-ol

Product Name:oxan-4-ol

IUPAC Name:oxan-4-ol

Packing Unit	Available Stock	Price($)
CM103849-100g	in stock	Ǡœ
CM103849-500g	in stock	ǺǺş

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2081-44-9 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:2081-44-9; Molecular Formula:C5H10O2; Melting Point:-; Smiles Code:OC1CCOCC1; Density:

: Catalog Number:CM103849; Molecular Weight:102.13; Boiling Point:183°C at 760 mmHg; MDL No:MFCD00006633; Storage:Store at 2-8°C.

: Tetrahydropyrans; Tetrahydropyran is an organic compound consisting of a saturated six-membered ring containing five carbon atoms and one oxygen atom. Tetrahydropyrans are common structural motifs in natural products and synthetic therapeutic molecules. In nature, these six-membered oxygen heterocycles are usually assembled by intramolecular reactions, including oxygen Michael addition or ring opening of epoxy alcohols. In fact, polyether natural products have been particularly extensively studied for their fascinating structures and important biological properties; these are often formed through endoselective epoxy open cascades.

: Pyrans; Pyrans are an important class of six-membered heterocyclic compounds, non-aromatic rings, composed of five carbon atoms and one oxygen atom, and contain two double bonds. The molecular formula of pyran is C5H6O, and there are two isomers. Pyrans, together with benzo derivatives, form scaffolds for a variety of drug applications, many of which are approved and promising candidates in clinical trials and recently isolated bioactive natural products.

: SE-9; SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects.